AXGNHealthcare · Medical DevicesThe 11 Wall Street analysts covering Axogen, Inc. hold a median 12-month price target of $60 — +16.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 88 of 100 as at 4 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Axogen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (99): The shares have been drifting up relative to others.
Growth (54): Sales and profits are flat, shrinking, or growing more slowly than they were.
Size (30): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on AXGN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +16.8% from it.
Of the 20 most recent actions, 9 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 Oct 2026 | Barclays | Maintains | Overweight | $50 → $60 |
| 29 Oct 2026 | Canaccord Genuity | Maintains | Buy | $55 → $60 |
| 29 Oct 2026 | HC Wainwright & Co. | Maintains | Buy | $53 → $56 |
| 29 Oct 2026 | Leerink Partners | Maintains | Outperform | $52 → $56 |
| 29 Oct 2026 | Truist Securities | Maintains | Buy | $53 → $60 |
| 29 Oct 2026 | Wells Fargo | Maintains | Overweight | $48 → $56 |
| 23 Oct 2026 | Barclays | Maintains | Overweight | $55 → $50 |
| 12 Oct 2026 | B of A Securities | Initiates | Buy | $52 |
| 12 Oct 2026 | B of A Securities | Initiates | Buy | — |
| 7 Oct 2026 | Barclays | Initiates | Overweight | — |
| 7 Oct 2026 | Barclays | Initiates | Overweight | $55 |
| 1 Oct 2026 | Truist Securities | Maintains | Buy | $60 → $53 |
| 1 Oct 2026 | Truist Securities | Maintains | Buy | — |
| 25 Sept 2026 | Raymond James | Maintains | Outperform | $48 → $53 |
| 25 Sept 2026 | Raymond James | Maintains | Outperform | — |
| 26 Aug 2026 | Truist Securities | Initiates | Buy | $60 |
| 26 Aug 2026 | Truist Securities | Initiates | Buy | — |
| 30 July 2026 | Canaccord Genuity | Maintains | Buy | — |
| 30 July 2026 | Canaccord Genuity | Maintains | Buy | $50 → $55 |
| 30 July 2026 | Citizens | Maintains | Market Outperform | $50 → $55 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
AXGN appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Axogen, Inc. returned +116.0% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 99% of US stocks
Cheaper than 12% of US stocks
Cheaper than 16% of US stocks
Cheaper than 98% of US stocks
Higher than 75% of US stocks
Higher than 91% of US stocks
Higher than 85% of US stocks
Higher than 47% of US stocks
Higher than 19% of US stocks
Higher than 36% of US stocks
Higher than 37% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Axogen, Inc. has a market value of $3.0B and an enterprise value of $2.6B.
Revenue in the twelve months to 30 June 2026: $251.2M. The latest quarter grew 26.2% year on year.
Net income over the same four quarters: −$33.5M, a −13.4% net margin.
Diluted earnings per share, trailing twelve months: $−0.68.
Free cash flow in the twelve months to 30 June 2026: $6.5M.
Trailing P/E: −145.6×; forward P/E: 70.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Axogen, Inc. employs 622 people — $404K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Axogen, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Axogen announced that its management is scheduled to participate in three upcoming investor conferences.
Why it matters — The announcement informs AXGN watchers of planned management participation at investor conferences.
Zacks compares Globus Medical (GMED) and AxoGen (AXGN) for investors interested in undervalued stocks in the Medical - Instruments sector.
Why it matters — The article frames AXGN alongside GMED in a comparison focused on valuation for sector investors.
Seeking Alpha describes Axogen as moving toward a default procedural platform in peripheral nerve repair, citing Q3 2026 revenue growth of 26% and adjusted EBITDA growth of 45%, alongside 2026 sales guidance of at least $290 million. It also highlights the $200 million BioCircuit (NerveTape) acquisition as a way to address technical barriers for surgeons and expand the addressable market.
Why it matters — The article frames Axogen’s growth, guidance, and acquisition as factors that could shape its position in peripheral nerve repair.
The item compares AxoGen’s year-to-date performance with BioCryst Pharmaceuticals and their sector. The excerpt does not provide performance results.
Why it matters — AXGN watchers may find the comparison relevant, but the excerpt does not indicate whether AxoGen outperformed.
AxoGen reported third-quarter revenue growth of 26.2%, citing increased demand across several markets for its nerve-repair products. After acquiring BioCircuit in October, the company raised its full-year revenue outlook and said it plans to begin prostate nerve reconstruction market-development activities in 2027.
Why it matters — The update highlights growth across existing markets, a higher revenue outlook, and a planned future market-development initiative.
The 11 Wall Street analysts covering Axogen, Inc. have a median 12-month price target of $60, with estimates ranging from $56 to $65. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 11 analysts covering Axogen, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Axogen, Inc. 88 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, Axogen, Inc. ranks 88 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).
No one can know that. What the data says: the median 12-month target from 11 analysts implies +16.8% from the last close, and Ticker Nerd's factor model ranks Axogen, Inc. 88 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Axogen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AXGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $56 to $65 over the next 12 months.
Axogen, Inc. returned +116.0% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Axogen, Inc. is a medical technology company focused on peripheral nerve regeneration and repair.
The most recent item we track (GlobeNewsWire, 3 Nov 2026): "Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences". Axogen announced that its management is scheduled to participate in three upcoming investor conferences.
Axogen, Inc. is a medical technology company focused on peripheral nerve regeneration and repair. Axogen develops and commercializes surgical solutions used by surgeons and healthcare providers to address nerve injuries caused by trauma, procedures, or disease. Its current product portfolio includes nerve allografts, nerve connectors, nerve protectors, nerve caps, and soft tissue membranes designed to support nerve reconstruction, protection, and functional restoration. The company serves hospitals, surgery centers, military hospitals, and specialists in reconstructive, hand, orthopedic, plastic, and oral and maxillofacial surgery. Axogen plays a specialized role in the medical devices market by offering targeted technologies for peripheral nerve care and by supporting clinical education around surgical treatment of nerve damage. Headquartered in Alachua, Florida, Axogen remains focused on a niche segment of regenerative medicine and surgical reconstruction.
CEO Mr. Michael D. Dale · 622 employees · United States · https://www.axogeninc.com
